Vorinostat - Unravel Biosciences
Alternative Names: RVL-001Latest Information Update: 04 Dec 2025
At a glance
- Originator Unravel Biosciences
- Class Antineoplastics; Hydroxamic acids; Small molecules
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Yes - Rett syndrome
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Pitt-Hopkins syndrome; Rett syndrome
Most Recent Events
- 02 Dec 2025 The Colombian Health Regulatory Agency (INVIMA). approves clinical trials application for RVL 001 in Rett syndrome and Pitt Hopkins syndrome .
- 02 Dec 2025 Unravel Biosciences plans a phase I trial for Rett syndrome(In children, In adolescents, In adults) in Colombia (PO, Suspension) (NCT07150013)
- 02 Sep 2025 Unravel Biosciences plans a phase I trial for Pitt Hopkins Syndrome (In children, In adolescents, In adults) in Colombia (PO, Suspension) (NCT07150026)